Medicinal formulation containing a combination of hiv type i and hiv type ii

Abstract

A novel medicinal formulation for the treatment of autoimmune diseases, said formulation comprising, combined serially diluted and potentized HIV TYPE I virus and HIV TYPE II virus, said dilution being effected in a vehicle selected from a group consisting of distilled water or ethyl alcohol and mixture of distilled water and ethyl alcohol.

1 . A novel medicinal formulation for the treatment of autoimmune diseases, said formulation comprising, combined serially diluted and potentized HIV TYPE I virus and HIV TYPE II virus, said dilution being effected in a vehicle selected from a group consisting of distilled water or ethyl alcohol and mixture of distilled water and ethyl alcohol. 
   
   
       2 . A formulation as claimed in  claim 1 , wherein the substances are obtained from sera, blood and body fluids of infected persons. 
   
   
       3 . A formulation as claimed in  claim 1 , wherein each of the serially diluted substances are 1 c dilutions of the original mixed HIV TYPE I and II substances in the vehicle, each ‘c’ representing a dilution of the previous stage in the vehicle where the proportion of the substance to vehicle is in the range of 1:99 to 50:50. 
   
   
       4 . A formulation as claimed in  claim 1 , wherein the serial dilution is in the range of 1 c to 1 million c. 
   
   
       5 . A process for making a formulation as claimed in  claim 1 , comprising the following steps
 i. obtaining predetermined quantity of HIV TYPE I substance,   ii. obtaining predetermined quantity of HIV TYPE II substance,   iii. mixing equal quantity of HIV TYPE I and HIV TYPE II,   iv. diluting mixture in step (iii) with appropriate amount of vehicle to obtain a primary dilution of 1 c potency,   v. serially diluting with potentization, the primary dilution of 1 c potency in step (iv) with the vehicle in a ratio of original dilution to vehicle in the range of 1:99 to 50:50 to obtain diluted and potentized HIV combination of 1 c to 1 million c and more.   
   
   
       6 . A process for making a formulation as claimed in  claim 5 , wherein potentization is effected by stroking by holding a bottle containing the diluted culture in a closed fist and striking the fist on a hard surface repeatedly at a regular frequency or by exercising similar powerful stroke using a mechanical device which can strike a bottle on a hard surface. 
   
   
       7 . A process for making a formulation as claimed in  claim 6 , wherein strokes are given about 10 times. 
   
   
       8 . A process for making a formulation as claimed in  claim 6 , wherein the bottle containing the preparation for stroking for potentization is a securely stoppered glass bottle. 
   
   
       9 . A process for making a formulation as claimed in  claim 6  in which a mechanical device is used to exert a force of at least 6 dynes rhythmically at a frequency of 10 strokes in two minutes. 
   
   
       10 . A novel medicinal formulation for the treatment of immune diseases comprising combined, serially diluted, and potentized HIV TYPE I virus and HIV TYPE II virus,
 wherein said dilution of the combined HIV TYPE I virus and HIV TYPE II virus substances is being effected in a vehicle selected from the group consisting of water, ethyl alcohol and a mixture thereof.   
   
   
       11 . The formulation of  claim 10 , wherein the HIV TYPE I virus and HIV TYPE II virus substances are obtained from sera, blood or body fluids of an infected person. 
   
   
       12 . The formulation of  claim 10 , wherein each of the serial dilutions is 1 centesimal potency dilution of the original mixture of the HIV TYPE I virus and HIV TYPE II virus substances in the vehicle, and the centesimal potency represents a dilution of the substances in the vehicle in the range of 1:99 to 50:50. 
   
   
       13 . The formulation of  claim 10 , wherein the serial dilution is in the range of 1 centesimal potency to 1 million centesimal potency; and the centesimal potency represents a dilution of the substances in the vehicle in the range of 1:99 to 50:50. 
   
   
       14 . A process for preparing a medicinal formulation of  claim 10 , comprising:
 (i) obtaining a HIV TYPE I virus substance;   (ii) obtaining a HIV TYPE II virus substance;   (iii) mixing equal quantity of the HIV TYPE I virus substance and the HIV TYPE II virus substance,   (iv) diluting the resultant mixture of step (iii) with a vehicle to obtain 1 centesimal potency; and   (v) serially diluting with potentization the resultant mixture of step (iv) with a vehicle in a ratio ranging from 1:99 to 50:50 to obtain a diluted and potentized HIV combination of 1 centesimal potency to 1 million centesimal potency and more.   
   
   
       15 . The process of  claim 14 , wherein the substances are obtained from sera, blood or body fluids of an infected person. 
   
   
       16 . The process of  claim 14 , wherein the potentization is effected by stroking, wherein the stroking is performed by holding a bottle containing the diluted substances in a closed fist, and striking the fist on a hard surface repeatedly at a regular frequency or by exercising similar powerful stroke using a mechanical device which strikes the bottle on a hard surface. 
   
   
       17 . The process of  claim 16 , wherein the strokes are given about 10 times. 
   
   
       18 . The process of  claim 16 , wherein the bottle is a securely stoppered glass bottle. 
   
   
       19 . The process of  claim 16 , wherein the mechanical device is used to exert a force of at least 6 dynes rhythmically at a frequency of 10 strokes in two minutes. 
   
   
       20 . A novel medicinal formulation prepared by the process of  14 .